GlassScriptPhysician profile
Rodel A Cacas
NPI 1568752236
$5,460.02
in general payments reported to CMS, 2019-2025
44 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $807 · 2021: $994 · 2022: $1,052 · 2023: $98.72 · 2024: $421 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $800.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $526.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $490.38 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $404.97 | 2019-2025 | Breztri |
| Pfizer INC. | $381.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $225.78 | 2019-2022 | |
| Allergan, INC. | $207.97 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.20 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $158.41 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $152.90 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $137.14 | 2019-2022 | |
| Renalytix Ai, INC. | $133.31 | 2022 | |
| Insulet Corporation | $132.63 | 2019-2025 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $127.48 | 2022 | |
| Amgen INC. | $120.31 | 2020-2025 | Repatha, Otezla, Repatha |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $113.00 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $106.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $95.83 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.72 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $81.77 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $73.33 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $64.54 | 2021 | |
| Lundbeck LLC | $61.06 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $55.54 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.29 | 2021-2025 | Caplyta |
| Tandem Diabetes Care, INC. | $41.91 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mylan Specialty L.P. | $41.08 | 2024 | Yupelri |
| Viatris Specialty LLC | $39.58 | 2025 | Yupelri |
| Abbott Laboratories | $38.92 | 2024-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $38.50 | 2025 | Xyosted |
| Medtronic, INC. | $36.81 | 2025 | Minimed 780g |
| Inspire Medical Systems, INC. | $32.57 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $29.95 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.63 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.98 | 2019-2020 | |
| Kyowa Kirin, INC. | $20.98 | 2025 | |
| Genentech USA, INC. | $20.92 | 2020 | |
| Philips North America LLC | $17.96 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Almatica Pharma LLC | $15.83 | 2024 | Teriparatide, Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $15.83 | 2025 | |
| Axsome Therapeutics, INC. | $14.03 | 2023 | Auvelity |
| Shire North American Group INC | $13.88 | 2019 | |
| Tolmar, INC. | $13.48 | 2025 | Jatenzo |
| Gilead Sciences, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodel Cacas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.